- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01327521
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma
Primary Objective:
To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE.
Secondary Objectives:
- To determine the progression-free survival of TACE vs. CyberKnife SBRT
- To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC
- To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
California
-
Stanford, California, Forenede Stater, 94305
- Stanford University School of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Confirmed hepatocellular carcinoma by one of the following:
- Histopathology
- One radiographic technique that confirms a lesion >=2 cm with arterial enhancement with washout on delayed phase
- Hepatic lesion in patients for whom surgical resection is not possible or would not result in an opportunity for cure
- Radiographic evidence of persistent, progressive or recurrent disease in an area previously treated with TACE. This evaluation should be determined after 6 weeks of initial TACE
Multi-specialty evaluation whereby the recurrent liver lesion was deemed by both the attending radiation oncologist and interventional radiologist amenable to treatment by the respective modality
- Eligible patients must undergo an IV contrast CT scan of the liver within 6 weeks of enrollment onto the study; a contrast enhanced liver MRI may be substituted for the IV contrast CT of the liver.
- A recent serum AFP must also be obtained within 4 weeks of enrollment.
- Unifocal liver tumors not to exceed 7.5 cm in greatest axial dimension. Multifocal lesions will be restricted to lesions that can be treated within a single target volume within the same liver segment and to an aggregate of 7.5cm as long as the dose constraints to normal tissue can be met
- Eastern Clinical Oncology Group performance status 0, 1 or 2
- Patients with liver disease classified as Child Pugh class A/B; if Child's class B, score must be 8 or less
- Albumin >= 2.5 g/dL
- Total bilirubin <= 3 mg/dL
- INR <= 1.5
- Creatinine <= 2.0 mg/dL
- Age >= 18 years old
- Life expectancy>= 6 months
- Ability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Prior radiation for the recurrent liver tumors
- Prior radiotherapy to the upper abdomen
- Prior RFA to index lesion
- Liver transplant
- Tumors >= 7.5 cm in greatest axial dimension
- Portal vein thrombus
- Large varices within 2 cm of index lesion (seen on cross section imaging)
- Contraindication to receiving radiotherapy
- Active gastrointestinal bleed within 2 weeks of study enrollment
- Ascites refractory to medical therapy
- Women who are pregnant
- Administration of any systemic chemotherapy within the last 1 month
- Presence of multifocal lesions located in different lobes of the liver or extrahepatic metastases
- Participation in another concurrent SYSTEMIC treatment protocol
- Prior history of malignancy other than HCC
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Freedom from local progression at 6 months and 12 months
Tidsramme: 6 months and 12 months
|
6 months and 12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Progression-free survival
Tidsramme: at 6, 12 and 18 months
|
at 6, 12 and 18 months
|
Overall survival
Tidsramme: at 6, 12, 18 months and up to 3 years
|
at 6, 12, 18 months and up to 3 years
|
Serum AFP levels
Tidsramme: 1 month, 3 months, 6 months, 12 months and 18 months
|
1 month, 3 months, 6 months, 12 months and 18 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Adenocarcinom
- Neoplasmer, kirtel og epitel
- Neoplasmer i fordøjelsessystemet
- Leversygdomme
- Neoplasmer i leveren
- Karcinom
- Carcinom, hepatocellulært
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Alkyleringsmidler
- Topoisomerase II-hæmmere
- Topoisomerasehæmmere
- Antibiotika, antineoplastisk
- Gemcitabin
- Cisplatin
- Fluorouracil
- Epirubicin
- Doxorubicin
- Maleinsyre
- Mitomyciner
- Mitomycin
Andre undersøgelses-id-numre
- HEP0030
- ACCH001.0 (Anden identifikator: Accuray Inc.)
- SU-05052010-5862 (Anden identifikator: Stanford University)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Carcinom, hepatocellulært
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk Ureter Urothelial Carcinoma | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Metastatisk nyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Metastatisk Urothelial Carcinom | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret nyrebækken Urothelial Carcinoma | Lokalt... og andre forholdForenede Stater
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.Trukket tilbageMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Uoperabelt nyrebækken Urothelial Carcinom | Uoperabelt Ureter Urothelial CarcinomaForenede Stater
-
All India Institute of Medical Sciences, New DelhiUkendtHOVED- OG NAKKEKRÆFT | CARCINOMA OROPHARYNX | CARCINOMA PYRIFORM SINUS | CARCINOMA LARYNXIndien
-
Barbara Ann Karmanos Cancer InstituteBristol-Myers SquibbAfsluttetStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
National Cancer Institute (NCI)RekrutteringNyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
National Cancer Institute (NCI)AfsluttetNivolumab til behandling af patienter med tilbagevendende og/eller metastatisk nasopharyngeal cancerTilbagevendende nasopharynx carcinom | Stadie III Nasopharyngeal Carcinoma AJCC v7 | Stadie IV Nasopharyngeal Carcinoma AJCC v7 | Stadie IVA Nasopharyngeal Carcinoma AJCC v7 | Stadie IVB Nasopharyngeal Carcinoma AJCC v7 | Stadie IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal ikke-eratiniserende...Forenede Stater, Singapore, Kina
-
National Cancer Institute (NCI)RekrutteringStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7 | Muskelinvasiv blære Urothelial CarcinomForenede Stater
-
University of California, San FranciscoAmgenTrukket tilbageStadie 0a Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie 0 er blæreurothelial karcinom AJCC v6 og v7 | Stadie I Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie 0 Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Fase III Ureterkræft AJCC v7 | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret Ureter Urothelial Carcinoma | Lokalt avanceret Urothelial Carcinom | Lokaliseret nyrebækken og Ureter Urothelial Carcinoma | Stadie II Blære Urothelial... og andre forholdForenede Stater, Guam
Kliniske forsøg med Cisplatin
-
West China Second University HospitalRekrutteringNeoadjuverende kemoterapi | Epitelkarcinom, ovarieKina
-
Cedars-Sinai Medical CenterRekrutteringHPV-positivt orofaryngealt planocellulært karcinomForenede Stater
-
Privo TechnologiesNational Cancer Institute (NCI)AfsluttetOralt planocellulært karcinomForenede Stater
-
Insmed IncorporatedAfsluttetOsteosarkom MetastatiskForenede Stater
-
Lawson Health Research InstituteRekrutteringLokalt avanceret hoved- og halspladecellekarcinomCanada
-
Sun Yat-sen UniversityAktiv, ikke rekrutterendeNasopharyngealt karcinomKina
-
Taiho Oncology, Inc.Quintiles, Inc.AfsluttetMavekræftForenede Stater, Canada
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial... og andre samarbejdspartnereAktiv, ikke rekrutterendeNasopharyngealt karcinom | Nasopharyngeale neoplasmer | Nasopharyngeale sygdomme | Neoplasma i hoved og halsKina
-
Fujian Cancer HospitalIkke rekrutterer endnuNasopharyngealt karcinomKina
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Afsluttet